Otonomy to Present at Cowen and Company Health Care Conference
Get Alerts OTIC Hot Sheet
Join SI Premium – FREE
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that David A. Weber, Ph.D., president and chief executive officer, will present at the 38th Annual Cowen and Company Health Care Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET (9:00 a.m. PT) at the Marriot Copley Place in Boston.
A live audio webcast of the presentation will be available through the Events and Presentations page of the company's website (www.otonomy.com).
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for otology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.
Contacts: Media InquiriesCanale CommunicationsHeidi Chokeir, Ph.D.Senior Vice President619.849.5377[email protected]
Investor InquiriesWestwicke PartnersRobert H. UhlManaging Director858.356.5932[email protected]
Source: Otonomy, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Skycrest Asset Management Launches Operations and Appoints Adrian Lim to Lead Global Equity Research Framework
- stackArmor Receives FedRAMP High Authorization for The Armory
- Energy Storage Canada releases new report on unlocking Ontario’s distributed energy storage resources, with research support from Peak Power
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share